GlassScriptPhysician profile
Mauricio Pedroza
NPI 1265744692
$3,424.11
in general payments reported to CMS, 2019-2025
22 companies · $853 in 2025
The $853 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $315 · 2021: $131 · 2022: $362 · 2023: $547 · 2024: $820 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $575.90 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $552.94 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $365.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.94 | 2022-2025 | |
| Amgen INC. | $202.64 | 2019-2024 | Tavneos, Parsabiv |
| Ardelyx, INC. | $192.27 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $131.11 | 2022-2023 | Benlysta |
| Akebia Therapeutics INC | $130.29 | 2020-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $117.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.17 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $97.19 | 2024-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $96.12 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $85.66 | 2022-2025 | Tarpeyo |
| Genzyme Corporation | $74.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.60 | 2024-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.26 | 2025 | Livtencity |
| Fresenius USA Marketing, INC. | $56.91 | 2022-2023 | Velphoro, Korsuva |
| Cormedix INC. | $44.92 | 2025 | Defencath |
| Mallinckrodt Hospital Products INC. | $43.38 | 2020-2024 | Acthar |
| Leadiant Biosciences, INC. | $37.73 | 2023 | Carnitor |
| Ani Pharmaceuticals, INC. | $33.45 | 2024 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $23.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Pedroza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.